Active, not recruitingPhase 2NCT03110978
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
Studying Gastroenteric neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Joe Y ChangM.D. Anderson Cancer Center
- Intervention
- Nivolumab(biological)
- Enrollment
- 140 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2026
Study locations (3)
- MD Anderson in The Woodlands, Conroe, Texas, United States
- M D Anderson Cancer Center, Houston, Texas, United States
- MD Anderson West Houston, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03110978 on ClinicalTrials.govOther trials for Gastroenteric neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.